© ipopba iStockphoto

What did we learn in Cardiology in 2020?

Contenu en français

The year 2020 has been particularly exciting in the field of cardiology. Numerous publications and guideline updates have been released, offering new insight into the understanding and treatment of cardiovascular diseases. This article provides an overview of the landmark publications in 2020 and early 2021, covering chronic coronary syndrome (CCS), transcatheter aortic valve implantation (TAVI), sudden cardiac death prevention, atrial fibrillation (AF) treatment and more promising results for SGLT2 inhibitors in the treatment of heart failure.

The randomized double-blind trial LoDoCo21 confirmed findings of the exploratory studies LoDoCo and COLCOT2,3 (benefit of colchicine in patients with CCS and myocardial infarction, respectively). The trial showed that in a population of >5000 patients with CCS randomized either to placebo or colchicine, the latter significantly decreased the endpoint of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization at 5 years (HR: 0.69; 95% CI: 0.57 to 0.83; p<0.001). These results are consistent with those obtained in the two other trials and, therefore, support the potential benefit of anti-inflammatory therapy in patients with CCS which might be incorporated in future guidelines.

Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:


Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)


Back to top